We describe the development of a highly specific, mulitplexed targeted proteomic LC-MS/MS assay for accurate quantitation of immunoprotective-proteins (including several classes of antibodies and complement) to SARS CoV2 S1 spike protein. We demonstrate how antibodies/complement levels can be monitored in response to vaccination with or without previous infection and show their altered level of protection against variants of concern.